20-10-2021, 07:59 AM
20-10-2021, 08:02 AM
Valneva Reports Positive Phase 3 Results for Inactivated
October 18, 2021
VLA2001 successfully met both co-primary endpoints
VLA2001 induced broad T-cell responses with antigen-specific IFN-gamma-producing T-cells against the S, M and N proteins.
VLA2001 was well tolerated, demonstrating a statistically significant better tolerability profile compared to active comparator vaccine
https://valneva.com/press-release/valnev...e-vla2001/
October 18, 2021
VLA2001 successfully met both co-primary endpoints
- Superior neutralizing antibody titer levels compared to active comparator vaccine, AstraZeneca’s AZD1222 (ChAdOx1-S)
- Neutralizing antibody seroconversion rate above 95%
VLA2001 induced broad T-cell responses with antigen-specific IFN-gamma-producing T-cells against the S, M and N proteins.
VLA2001 was well tolerated, demonstrating a statistically significant better tolerability profile compared to active comparator vaccine
https://valneva.com/press-release/valnev...e-vla2001/